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Received June 8, 2010; accepted December 16, 2010AbstractBackground: Anticonvulsants are regarded as useful for the treatment of neuropathic pain. In this study, we evaluated the efficacy and occurrence
of side effects of lamotrigine (LTG) in comparison with carbamazepine (CBZ), in trigeminal neuralgia (TN) patients.
Methods: The study was an interventional and crossover comparison. Twenty-one patients with TN were administered with LTG in comparison
to CBZ. The clinical trials comprised two phases of 40 days each, with an intervening three-day washout period. The final titration in dose for
LTG was 400 mg and 1,200 mg for CBZ. Efficacy of the medications involved was determined by visual analog scale (VAS) and verbal rating
scale (VRS). Side effects were recorded through marking of the profiles of side effects encountered on administration of LTG and CBZ, together
with baseline haematological, hepatic and renal investigations.
Results: Both on VAS and VRS assessments, in terms of proportion of patients, CBZ benefitted 90.5% (19/21) of the patients with pain relief
( p < 0.05), in contrast to 62% (13/21) from LTG. On VAS assessment, of the 13 patients who gained pain relief from LTG and 19 from
CBZ, 77% (10/13) obtained a “complete” degree of pain relief from LTG, as compared with 21% (4/19) from CBZ. On VRS assessment,
with LTG, 84% (11/13) of the patients accomplished “much better” degree of pain relief, as compared with 26% (5/19) with CBZ. On LTG,
67% (14/21) of patients endured general pharmacological side effects, as compared with 57% (12/21) of patients on CBZ ( p > 0.05).
Meanwhile, LTG inflicted 14% (3/21) of the patients with haematological, hepatic and renal derangements, as compared with 48% (10/21)
on CBZ.
Conclusion: LTG is generally an effective and safe treatment for management of TN, compared to CBZ.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Trigeminal neuralgia (TN) is a rare form of chronic facial
pain. Although not life-threatening, it can be excruciatingly
painful and extraordinarily debilitating. Its uniqueness and* This study is registered at ClinicalTrials.gov. The corresponding Clin-
icalTrials.gov ID for this study is NCT00913107.
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doi:10.1016/j.jcma.2011.04.002peculiarity can be ascertained by the fact that TN may present
to and be managed by dentists, neurologists, neurosurgeons,
oral surgeons and ear, nose and throat surgeons. The dental
surgeon is often the first to be consulted when patients confront
this tormenting condition and should be familiar with it, in
order to make an accurate diagnosis and initiate treatment.1,2
TN has an occurrence of approximately 4/100,000 indi-
viduals and occurs in both genders,3 having a higher occur-
rence in women, with 5.9 cases per 100,000 females, as
compared with men at 3.4 cases per 100,000 males.4,5 It is
a disease of older age groups, with a peak in the 50- to 70-year
age group, and is rare below 40.6
TN is characterized by recurrent attacks of lancinating pain
in the trigeminal nerve distribution. Typically, brief attacks arehinese Medical Association. All rights reserved.
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touch, or even a cool breeze. The pain is nearly always
unilateral, and may occur repeatedly throughout the day.7 The
pathophysiology of TN is thought to be focal mechanical
compression of the trigeminal nerve at a point close to the
brainstem, especially by an artery or tumor. This leads to
demyelination of the nerve and the generation of ectopic
impulses that spread ephaptically to precipitate the typical
attack of TN.7,8
The management of TN is initially medical. Carbamaze-
pine (CBZ) continues to be the treatment of choice,9 however
a substantial proportion of patients tolerate this drug poorly,
predominantly because of side effects that include drowsiness,
accommodation disorders, hepatitis, derangement in hepatic
enzymes, renal dysfunction, congestive heart failure, delayed
multi-organ failure, leucopenia, thrombocytopenia etc.10,11 If
pain relief for TN is incomplete with CBZ or it produces side
effects, other anticonvulsant drugs are suggested as alterna-
tives,6,7 such as LTG, baclofen, phenytoin, gabapentin, clo-
nazepam, valproate, mexiletine, and topiramate.6
Lamotrigine (LTG) has a bimodal mechanism of action: it
inhibits release of the excitatory neurotransmitter glutamate,
most likely by inhibiting voltage-sensitive sodium channels,
and is antagonistic at neuroexcitatory N-methyl-D-aspartate
receptors. It can also act at calcium channels.11e13 Glutamate
has been implicated in the mechanisms contributing towards
the phenomenon of chronic pain, such as sensitization and
wind-up. LTG, through its inhibition of pathological release of
glutamate has the potential for management of chronic pain,
particularly of neuropathic origin.10
LTG was found to be efficacious in a placebo-controlled
crossover trial in 14 patients with TN.10 An open-label study
determined the better clinical and humanistic outcomes of
LTG monotherapy compared with CBZ, phenytoin, or val-
proate monotherapy in patients with epilepsy.14 The effec-
tiveness of LTG when used as monotherapy in comparison
with CBZ rather than placebo has yet to be evaluated in TN
patients. And given the ethical and methodological dilemmas,
a placebo-controlled, randomized trial raises ethical concerns
in patients particularly with refractory TN, who are amongst
the most difficult to treat.10,15 This report presents the results
of a clinical study to assess the efficacy and safety of LTG in
direct comparison to an active “control” (CBZ), for TN.
2. Methods2.1. SubjectsSixteen previously and five newly diagnosed patients
suffering from TN were recruited into this study, conducted at
two centers within Malaysia. Ethical approval was granted by
the Faculty of Dentistry Medical Ethics Committee, University
of Malaya. All the prospective participants were provided with
“Patient Information Sheets”, containing thorough details and
information regarding this clinical study. Informed consent
was obtained from all patients before their enlistment. Patients
with TN from either sex with no age limitation were eligiblefor the study. Patients were ineligible for inclusion if any of
the following were evident: psychiatric illness, severe liver or
cardiovascular disease, renal impairment, low white cell count,
malignancy, pregnancy or lactation, alcohol or recreational
drug abuse, and positive tests for human immunodeficiency
virus or hepatitis B or C. Furthermore, it was ascertained
that only those previously diagnosed patients with TN were
recruited who were being treated with CBZ monotherapy only
and hadn’t undergone any cessation of CBZ (because of side
effects or lack of pain relief) ever since its initiation.2.2. Diagnosis of TNWalk-in patients, with pain in and around the face were
determined for the specific diagnosis of TN by using detailed
clinical history and examination as indispensable tools.
Furthermore, the Facial Pain Questionnaire (FPQ)16 was
employed to specify the TN patients into categories of
Trigeminal neuralgia type 1 (TN 1) and Trigeminal neuralgia
type 2 (TN 2). As per the FPQ interpretation, the explanation
of diagnosis for TN 1 and TN 2 is as follows:
 Trigeminal neuralgia type 1 (TN 1): “A facial pain of
spontaneous onset characterized by brief electric shock-
like pains, abrupt in onset and termination”, such that
the pain symptoms are limited to the duration of an
episode of pain (temporary pain).1,16
 Trigeminal neuralgia type 2 (TN 2): “A facial pain of
spontaneous onset characterized by brief electric shock-like
pains, abrupt in onset and with the features of a constant
background pain which is dull and vague”. This constant
pain might persist from a few minutes to a few hours.16,172.3. Study design and proceduresThis research study was of interventional type, having
experimental design features of a comparative, open, and
crossover clinical study. CBZ was employed as the “control”
for comparative purposes in order to check and evaluate the
efficacy (pain relief) and occurrence of side effects of LTG.
The clinical trials comprised two phases:
Phase 1 (clinical trial): At the start of Phase 1 of the
clinical trials, the 16 previously diagnosed TN patients who
were already receiving CBZ before this study as divulged
through their medical histories, were asked to stop its
administration, and subsequently after undergoing a three-
day washout period, were prescribed with LTG for the
following 40 days. Where as the 5 newly diagnosed patients
with TN, enrolled in this study were immediately
prescribed with CBZ for the next 40 days.
Phase 2 (clinical trial): At the end of the 40 days, 5 patients
who were on CBZ in Phase 1 were put on LTG, for the next
40 days. Similarly, at the end of treatment with LTG in
Phase 1, 16 patients were put on CBZ for the next 40 days.
An intervening three-day washout period was observed
between Phases 1 and 2.
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cation (LTG, 50 mg and 100 mg; CBZ, 100 mg and 200 mg)
were provided to the patients. The regimes for prescription of
LTG and CBZ for both Phases 1 and 2 of the clinical trials were
as follows: LTG was started at a dose of 100 mg/d, and with
a dose escalation of 100 mg/d on every 10th day, titrated up to
a target dose of 400 mg. CBZ was a started at a dose of
300 mg/d, and with a dose escalation of 300 mg/d on every
10th day, titrated up to a target dose of 1,200 mg.2.4. Outcome measuresThe inquiry maneuvers related to the determination of
efficacy of the medications involved was facilitated through
the usage of various diagnostic instruments and tools such as
the visual analog scale (VAS) and verbal rating scale (VRS).
Detailed clinical history was also availed as an indispensable
tool to divulge the required information about the nature of
complaint, efficacy and safety of the medications (CBZ and
LTG).
At the termination of each treatment phase, side effects
were recorded through marking of the profiles of side effects
encountered on administration of LTG and CBZ, together with
baseline haematological, hepatic and renal investigations.
These investigations included full blood counts (FBCs), liver
function tests (LFTs) and renal function tests (RFTs). All these
maneuvers were performed on the initiation, as well as at the
termination, of each of the two phases of the clinical trials.
Thus we compared the end of each treatment phase with the
pre-trial condition, each for CBZ and LTG.2.5. Interpretation of VAS and VRSTable 1
Efficacy status in relation to number of patients
Pain relief with LTG Pain relief with CBZ Total
Yes (n) No (n)The patients rated their current pain intensity (pi) and pain
relief (pr) on a VAS, a 100-mm vertical line with “no pain”
marked at one end and “worst imaginable pain” at the other,
and on a 3-category parametric VRS, before the start of
treatments (LTG and CBZ) and at each follow-up visit. VAS
ratings of 0e4 mm were considered no pain; 5e44 mm, mild
pain; 45e74 mm, moderate pain; and 75e100 mm, severe
pain. Toward pain relief, VAS ratings of 0e4 mm were
considered complete relief; 5e44 mm, fair amount of relief;
and 45e100 mm, incomplete relief. For VRS, pain intensity
was determined through parameters related to severity of pain
(0, none; 1, mild; 2, moderate; 3, severe) and its paroxysms
(none, 1e3, 4e7, 8e12, 13e20, >20), where as pain relief
was determined by a parameter based on three phrases related
to the degree of pain relief (much better, better and minimal
effect).
The difference between each post-treatment VAS and VRS
scores and the pre-treatment scores were calculated and rep-
resented each participant’s VAS and VRS difference scores.Yes (n) 13 0 13
No (n) 6 2 82.6. Statistical analysis
Total 19* 2 21
* A p value < 0.05.
CBZ ¼ carbamazepine; LTG ¼ lamotrigine; n ¼ number of patients.
Patients’ pre and post medication (LTG and CBZ)
responses towards their TN pain, recorded on VAS and VRSs,were translated into numerical values followed by statistical
analysis using SPSS version 15.0 (SPSS Inc., Chicago, IL,
USA). Chi-square test comprised the statistical analyses. For
analytical purposes related to the determination of efficacy and
safety of LTG in comparison with CBZ, each of these two
medications was taken as a separate entity, therefore the
clinical effects (i.e. efficacy and safety) of each of these
medications (LTG, CBZ) was subjected to statistical analysis
separately. A p value of less than 0.05 was considered to be
statistically significant.
3. Results3.1. Patients characteristicsThe two centres recruited seventeen and four patients
respectively. Of these 21 patients (male, n ¼ 9; female,
n ¼ 12) assessed under this study, female comprised 57% of
the patients, representing a female to male ratio of 1.33:1. The
mean age of patients was 64.66 years with a standard deviation
of 13.22 years. The youngest patient, a female of 32 years and
the oldest, a male, aged 84 years.
Eighteen cases (86%), through their clinical presentations
and subsequent input of the features of their ailment into the
online version of the FPQ, were diagnosed with TN 1,whereas
three patients (14%) were diagnosed with TN 2.3.2. Efficacy analysisBoth on VAS and VRS assessments, out of the total of
21 patients, 13 patients (62%) attained pain relief from LTG in
contrast to 19 (90.5%) attaining pain relief from CBZ. Eight
patients (38%) failed to achieve any benefit of pain relief from
LTG, whereas 2 patients (10%) failed to achieve any benefit of
pain relief from either drug. Under CBZ, the p value of the test
was 0.001 (<0.05) indicating a large proportion of patients
benefited in pain relief from CBZ. Table 1 illustrates the
numbers of patients benefitting from pain relief under LTG
and CBZ.3.3. Degrees of pain relief assessed by VAS and VRSOn VAS assessment, of a total of 13 patients attaining pain
relief from LTG, 10 patients (77%) experienced “complete”
pain relief, whereas among the 19 patients who experienced
pain relief with CBZ, only 4 patients (21%) experienced
“complete” pain relief.
Table 3
Degree of pain relief assessed by verbal rating scale
Degree of pain relief LTG CBZ
Much better 11 (84%) 5 (26%)
Better 1 (8%) 7 (37%)
Minimal effect 1 (8%) 7 (37%)
Total 13 (100%) 19 (100%)
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pain relief from LTG, 11 patients (84%) accomplished “much
better” degree of pain relief. While among the 19 patients who
experienced pain relief with CBZ, only 5 patients (26%)
accomplished “much better” degree of pain relief. Tables 2
and 3 elaborate the degrees of pain relief on VAS and VRS
assessments.CBZ ¼ carbamazepine; LTG ¼ lamotrigine.
3.4. Safety analysisTable 4
General side effects attributable to lamotrigine and carbamazepine
Side effects LTG (n ¼ 14)*,a CBZ (n ¼ 12)*,a
Total side effects 21 22
Headache 4 10
Dizziness 3 5
Accommodation disorders e 1
Mental irritability and distress 2 1The general side effects reported on administration of LTG
and CBZ are listed in Table 4. Fourteen patients (67%) out of
a total of 21 patients during therapy with the LTG displayed 21
pharmacological side effects attributable to LTG, whereas 12/
21 (57%) of the patients displayed 22 pharmacological side
effects attributable to CBZ. Skin rash, headache and dizziness
were the most commonly reported side effects on LTG. Eight
patients (38%) withdrew from LTG because of development of
skin rash (5 patients) and the failure to obtain pain relief (3
patients). Two patients (10%) withdrew from CBZ because of
the development of Stevens-Johnson syndrome. Statistically,
the proportion of patients with side effects was no different
from that of those who did not have side effects, on either of
the two treatments ( p > 0.05).
For the sake of comparative assessment of the safety level
of LTG and CBZ, patients were assigned into three categories
based on affliction of side effects on administration of LTG
and CBZ (Table 5). Patients who suffered side effects (8
patients), as well as no side effects (3 patients), through both
treatments (LTG, CBZ) were classified as a group with “No
difference”. Patients who had side effects with LTG but not
with CBZ were classified as “Worse” and patients having side
effects with CBZ but not with LTG were classified as “Safer”.
On statistical comparison of the “Worse” and “Safer” statuses,
the safety status of LTG was no different from that of CBZ
( p > 0.05).
Haematological, hepatic and renal side effects with
derangement values are illustrated in Table 6. LTG rendered 3
patients (14%) with these side effects. The most common of
them pertains to the alterations within the red blood cell
counts, haematocrit (packed cell volume) and haemoglobin
levels. LTG had no effect on white blood cell and platelet
counts. CBZ rendered 10 patients (48%) with haematological,
hepatic and renal side effects. Derangements within the red
blood cell counts and haematocrit levels were the most
commonly reported events on CBZ. Regarding the derange-
ments in LFT and RFT profiles (Table 6), LTG resulted inTable 2
Degree of pain relief assessed by visual analogue scale
Degree of pain relief LTG CBZ
Complete 10 (77%) 4 (21%)
Fair 2 (15%) 8 (42%)
Incomplete 1 (8%) 7 (37%)
Total 13 (100%) 19 (100%)
CBZ ¼ carbamazepine; LTG ¼ lamotrigine.derangement of the alkaline phosphatase (liver enzyme) in two
patients, while CBZ resulted in derangement of the gamma
glutamyl transpeptidase (liver enzyme) in two patients, as
determined by LFT. An abnormal shift in the creatinine levels
determined by RFT was detected in one patient while on LTG
and in two patients while on CBZ. No statistical analysis was
appropriate, as a fewer number of patients were inflicted with
haematological, hepatic and renal side effects on either drug.
4. Discussion
The design and methodology of clinical drug trials to
investigate the efficacy (pain relief) and safety (side effects) of
new drugs for managing TN presents a substantial challenge to
the investigator as well as to the patients. The ethical
considerations expect that the participants of the trial will not
be subjected to unbearable afflictions of TN, at the expense of
gathering some relevant clinical data pertaining to the new
treatment in question. Sequential trials comparing new anti-
convulsant drugs with a positive control have the potential to
combine scientific validity, clinical relevance, and ethical
acceptability. A trial of this sort involving evaluation of the
“active” medication (LTG for this particular study) assessed in
direct comparison to an active “control” (CBZ), serves two
purposes. Firstly, it avoids the concerns raised by exposing
patients with agonizing and distressing pain of TN to placebo.
Secondly, it brings into limelight the side effects and short-
comings of the established treatment (CBZ). Finally the
broader aim of such a design would be to show superiority, ifNausea and GI troubles e 3
Allergic reactions (skin rash &
Stevens-Johnson syndrome)
5 2
Altered taste sensation 2 e
Hot flashes/pyretic feeling 3 e
Increased micturition (polyurea) 1 e
Resp. problems (asthma) 1 e
a Number of reported side effects.
* A p value > 0.05.
CBZ ¼ carbamazepine; GI ¼ gastrointestinal; LTG ¼ lamotrigine; n ¼ number
of patients reporting side effects.
Table 5
Safety of LTG compared to carbamazepine
Safety status Patients (%)
Worse with LTG 6 (29%)*
Safer with LTG 4 (19%)*
No difference 11 (52%)
* A p value > 0.05.
LTG ¼ lamotrigine.
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guarantee its equivalence if not.15
The clinical trials for this study were designed with the
aforementioned considerations in mind. In this comparative
study, LTG was assessed for its efficacious capability and the
safety potential, for the management of TN. For that purpose,Table 6
Haematological, hepatic and renal side effects
Side effects LTG (n ¼ 3)
Y in limit (# of patients) [ in lim
I. Cellular profiles
(A) Full blood counts (FBCs)
1) Derangements in
RBC levels (normal range:
4.5e5.9  1012/L)
4.18  1012/L
(2)
7.43  1
(1)
2) Derangements in haematocrit
levels (normal range:
36e46%)
30%
(2)
72%
(1)
3) Derangements in
haemoglobin levels (normal
range: 120e160 g/L)
115 g/L
(2)
237 g/L
(1)
4) Derangements in WBC levels
(normal range:
4.6e10.2  109/L)
e e
5) Derangements in platelet
levels (normal range:
150e400  109/L)
e e
6) Elevation in blood urea
(normal range:
1.7e8.3 mmol/L)
e e
II. Molecular profiles
(A) Liver function tests (LFTs)
1) Derangement in liver enzymes
1a) Alkaline phosphatase
(normal range:
50e136 IU/L)
131 IU/L
(1)
162 IU/L
(1)
1b) Gamma glutamyl
transpeptidase (normal
range: 5e55 IU/L)
e e
2) Derangement in globulin
levels (normal range:
20e35 g/L)
30 g/L
(1)
38 g/L
(2)
(B) Renal function test (RFT)
1) Creatinine levels (normal
range: 53e100 mmol/L)
e 104 mmo
(1)
2) Electrolytes:
2a) Sodium (normal range:
136e145 mmol/L)
e e
2b) Chloride (normal range:
100e108 mmol/L)
e e
n ¼ total number of patients reporting haematological, hepatic and renal side effea comparative and sequential/ methodological approach was
undertaken related to LTG administration in the TN patients,
in direct comparison to an established effective treatment
(CBZ). Important consideration was also given to the strategy
of standardization related to the evaluation of the efficacy of
the medications (LTG, CBZ). This was addressed through
adoption of “Intention-to-treat” principle. When there is a drop
in the number of patients along the way during an experiment
because of the non-adherence to the procedures and protocols,
or clinicians’ recommendations for withdrawal of the medi-
cation(s) under study because of side effects, the end results
become uncertain. “Intention-to-treat” is a strategy to account
for this uncertainty which is generally interpreted as including
all the patients, regardless of whether they actually satisfied
the entry criteria, the treatment actually being received, onCBZ (n ¼ 10)
it (# of patients) Y in limit (# of patients) [ in limit (# of patients)
012/L 3.62  1012/L
(5)
6.39  1012/L
(1)
33.1%
(4)
62%
(1)
112 g/L
(2)
235 g/L
(1)
4.3  109/L
(1)
11.5  109/L
(1)
143  109/L
(1)
406  109/L
(1)
e 13 mmol/L
(1)
e e
50 IU/L
(1)
116 IU/L
(1)
17 g/L
(1)
37 g/L
(4)
l/L 42 mmol/L
(1)
114 mmol/L
(1)
132 mmol/L
(1)
e
99 mmol/L
(1)
e
cts.
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Furthermore, this strategy takes the last observation as the end
result.18,19 During this study, if some patients were to be
discontinued on either of the two treatments (LTG, CBZ), due
to development of the side effects or because of unbearable
TN pain as a result of failure of drugs’ efficacy, the pain relief
status at the time of discontinuation was considered as the
outcome. This was in accordance with the “Intention-to-treat”
principle.
CBZ, on initiation, has an elimination half-life of 20e40
hours. However, during chronic therapy, its half-life is
decreased to 11e27 hours consequent to autoinduction (i.e. it
induces its own hepatic metabolism). The mean elimination
half-life of LTG is about 24 hours.2 In this study of crossover
comparison, a washout period of three days between the
administration of two drugs was included to minimize carry-
over effects, which was expected to be sufficient for both LTG
and CBZ to be eliminated.
Because of scant numbers of patients suffering from
trigeminal neuralgia and the reluctance of some patients to
participate, it was imperative to include both the previously
and newly diagnosed patients. To ensure fairness in compar-
ison between LTG and CBZ, it was ascertained that only those
previously diagnosed patients would be recruited who were
solely on CBZ monotherapy ever since their diagnosis and
(these 16 patients) hadn’t discontinued CBZ in the past, either
because of lack of pain relief or because of life-threatening/
major side effects requiring withdrawal. Although they were
all benefitting from varied degrees of pain relief from their
CBZ medication before recruitment in this study, a washout
period of three days (observed at the initiation of the study)
was expected to be sufficient for the elimination of CBZ
rendering these patients as “new entities” with minimal
carryover effects. It is also pertinent to mention that no
consideration was given to the degree of pain relief (whatso-
ever) from the CBZ treatment gained prior to enlistment in this
study.
In this study, LTG was found to be an effective remedy for
the management of TN, even though a sizeable proportion of
patients derived benefit of pain relief from CBZ, but still, in
terms of degree of pain relief a greater proportion of patients
obtained a “complete” and “much better” degrees of pain
relief from TN with LTG compared with CBZ. The positive
efficacious characteristics of LTG shown by this study are in
general agreement with the findings of Zakrzewska et al,10
conducted to study the efficacy and tolerability of LTG in 14
patients with TN. In the present study, in terms of proportion
of patients benefitting from the pain relief, efficacy of CBZ
was found to be higher compared with that of LTG. This
finding was in accordance with the two clinical studies.20,21
Sato et al20 demonstrated a beneficial efficacy rate of 90.5%
for CBZ, in a diagnostic study to evaluate the significance of
CBZ in 50 TN patients. Silver et al.21 demonstrated a low
efficacy rate of LTG (<50%), in a clinical study to evaluate the
efficacy of LTG in 112 patients with neuropathic pain.
LTG, like CBZ, is not free from side effects. The numbers
of dropouts from this clinical study because of a characteristicside effect of skin rash was found to be higher with LTG.
Rapid dose escalation of LTG most likely increases the
chances of dose-dependent side effects, particularly skin rash.
The occurrence of skin rash requiring discontinuation of LTG
can be reduced by using a gradual introduction of the drug.10
The recommended dose escalation for LTG is to have it
initiated at 25 mg daily and to increase it by 25 mg every
seventh day as needed to a total daily dose of 400 mg.22
This clinical trial employed a far more rapid introduction of
LTG than is recommended, and should not be used in clinical
practice. However, gradual introduction of LTG can be
a limitational factor precluding the use of LTG in the most
severe cases of TN. LTG in this study proved to be a nominally
tolerated option, particularly with respect to a lower occur-
rence of central nervous system and haematologically related
side effects, which is a common occurrence with CBZ.10 The
present clinical trial was relatively short, with a total duration
of 20 weeks. Because of the painful condition of TN, longer
studies on the clinical trials would not be advisable. As such,
the effectiveness of LTG in the long-term treatment of TN
remains open to question. However, patients who are on
treatment with LTG may be monitored for its long-term
effects. It is also heartening to observe that thirteen (62%)
of the twenty-one patients in this trial remained on LTG even
after termination of the study and continued to receive the
benefit of pain relief.
In conclusion, the results of this study suggest that LTG is
an effective and safe treatment for management of TN,
compared to CBZ.Acknowledgments
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